研究硫酸化壳聚糖衍生物对实验性大鼠脂肪肝的治疗作用。采用定量灌胃酒脂乳剂的方法建立大鼠混合型脂肪肝模型。建模成功后的大鼠随机分为模型对照组和硫酸化壳聚糖治疗组,各组均饲以正常饲料,硫酸化壳聚糖治疗组采用腹腔注射给药,模型对照组以同等体积的生理盐水腹腔注射。治疗3周后,观察大鼠肝脏病理形态学变化,检测血清TC、HDL、LDL、AST、ALT和肝组织TG、AST、ALT、SOD含量。结果表明,硫酸化壳聚糖治疗组的肝组织形态较模型对照组有明显的好转,血清TC,HDL,LDL,AST,ALT和肝组织TG,AST,ALT含量显著降低,肝组织SOD含量增加;硫酸化壳聚糖治疗组血清TC,HDL,LDL,AST,ALT和肝组织TG,AST,ALT,SOD含量均恢复至正常对照组水平,硫酸化壳聚糖衍生物对大鼠脂肪肝有很好的治疗效果。

The purpose of this study is to investigate the therapeutic effect of sulfated chitosan derivatives on rat fatty liver.The model group was fed with Liquor-fat emulsion quantitatively.Five weeks later,when the establishment of experimental model of fatty liver was confirmed,the model rats were subdivided into model control group and sulfated chitosan derivative treated groups.Each group were fed with normal diet,sulfated chitosan derivative treated groups were administered by intraperitoneal injection,normal control group and model control group administered with an equal volume of physiological saline.Three weeks later,all rats were sacrificed for observing the pathological changes of liver,measuring serum TC,HDL,LDL,AST,ALT contents,and hepatic TG,AST,ALT,SOD levels.The results indicated that,compared to the model control group,sulfated chitosan derivative treated groups obviously improved pathological change,significantly reduced serum TC,HDL,LDL,AST,ALT contents,and hepatic TG,AST,ALT levels,and increased SOD level in liver.The serum TC,HDL,LDL,AST,ALT contents and hepatic TG,AST,ALT,SOD levels of sulfated chitosan derivative treated groups were restored to the level of normal control group.Therefore,the sulfated chitosan derivative has excellent therapeutic effect on experimental rat fatty liver.